Anbio Biotechnology
NNNN
$6.61
$0.040.61%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.33M | 3.29M | 2.25M | 1.89M | 1.52M |
| Total Depreciation and Amortization | 3.20K | 7.60K | 12.00K | 13.50K | 15.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -285.20K | -224.30K | -163.40K | -109.30K | -55.20K |
| Change in Net Operating Assets | -4.68M | -2.94M | -1.20M | 1.40M | 4.01M |
| Cash from Operations | -634.20K | 132.10K | 898.40K | 3.20M | 5.49M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 285.20K | 1.01M | 1.73M | 1.84M | 1.95M |
| Cash from Investing | 285.20K | 1.01M | 1.73M | 1.84M | 1.95M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 200.00 | 100.00 | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.00K | 27.60K | -42.80K | -149.30K | -255.80K |
| Cash from Financing | 98.20K | 27.70K | -42.80K | -149.30K | -255.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -250.80K | 1.17M | 2.59M | 4.88M | 7.18M |